Affiris AG

Industry · 20 registered clinical trials.

Status	Trial	Phase	Started
Completed	Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Parkinson's Disease	Phase 1	2016-02-02
Completed	Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in H Hypercholesterolemia	Phase 1	2015-07-01
Completed	Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA Multiple System Atrophy, Neurodegenerative Diseases	Phase 1	2014-12-11
Completed	Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease Parkinson Disease, Neurodegenerative Diseases	Phase 1	2014-12-01
Completed	Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activ Parkinson's Disease	Phase 1	2014-08-01
Terminated	Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Wh Alzheimer´s Disease	Phase 2	2013-06-01
Completed	AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immuniza Parkinson's Disease	—	2013-06-01
Completed	Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Di Parkinson's Disease	Phase 1	2012-02-01
Terminated	Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A Alzheimer's Disease	—	2011-12-01
Terminated	Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease Alzheimer´s Disease	—	2011-07-01
Completed	Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protei HDL, Drug Safety	Phase 1	2011-05-01
Completed	Safety and Tolerability of AFFITOPE AD03 Alzheimer's Disease	Phase 1	2010-10-01
Completed	Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD Alzheimer's Disease	Phase 2	2010-09-01
Completed	AD01 Follow up Extension Visit Alzheimer´s Disease	—	2010-09-01
Completed	Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02 Alzheimer's Disease	Phase 1	2009-10-01
Completed	Long-term Safety and Tolerability of AFFITOPE AD02 Alzheimer's Disease	—	2008-11-01
Completed	Long-term Safety and Tolerability of AFFITOPE AD01 Alzheimer's Disease	—	2008-06-01
Completed	Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Diseas Alzheimer's Disease	Phase 1	2008-02-01
Completed	Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Diseas Alzheimer's Disease	Phase 1	2007-07-01
Withdrawn	Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® Parkinson's Disease	Phase 1	—